Stockreport

Mesoblast's remestemcel-L shows 75% survival rate in children with severe form of graft-versus-host disease [Seeking Alpha]

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF Mesoblast's remestemcel-L shows 75% survival rate in children with severe form of graft-versus-host diseaseAdditional data from a Phase 3 clinical trial evaluating Mesob [Read more]